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Abstract. Calcific aortic valve disease (CAVD) involves 
progressive valve leaflet thickening and severe calcification, 
impairing leaflet motion. The in vitro calcification of primary 
rat, human, porcine and bovine aortic valve interstitial cells 
(VICs) is commonly employed to investigate CAVD mecha‑
nisms. However, to date, no published studies have utilised 
cell lines to investigate this process. The present study has 
therefore generated and evaluated the calcification potential 
of immortalized cell lines derived from sheep and rat VICs. 
Immortalised sheep (SAVIC) and rat (RAVIC) cell lines 
were produced by transduction with a recombinant lentivirus 
encoding the Simian virus (SV40) large and small T antigens 
(sheep), or large T antigen only (rat), which expressed markers 
of VICs (vimentin and α‑smooth muscle actin). Calcification 
was induced in the presence of calcium (Ca; 2.7 mM) in 
SAVICs (1.9 fold; P<0.001) and RAVICs (4.6 fold; P<0.01). 
Furthermore, a synergistic effect of calcium and phosphate 
was observed (2.7 mM Ca/2.0 mM Pi) on VIC calcification 
in the two cell lines (P<0.001). Analysis of SAVICs revealed 
significant increases in the mRNA expression of two key 
genes associated with vascular calcification in cells cultured 
under calcifying conditions, runt related transcription factor‑2 
(RUNX2;1.3 fold; P<0.05 in 4.5 mM Ca) and sodium‑dependent 
phosphate transporter‑1 (PiT1; 1.2 fold; P<0.05 in 5.4 mM Ca). 
A concomitant decrease in the expression of the calcification 
inhibitor matrix Gla protein (MGP) was noted at 3.6 mM Ca 
(1.3 fold; P<0.01). Assessment of RAVICs revealed alterations 
in Runx2, Pit1 and Mgp mRNA expression levels (P<0.01). 
Furthermore, a significant reduction in calcification was 
observed in SAVICs following treatment with established 
calcification inhibitors, pyrophosphate (1.8 fold; P<0.01) 
and etidronate (3.2 fold; P<0.01). Overall, the present study 
demonstrated that the use of immortalised sheep and rat VIC 
cell lines is a convenient and cost effective system to inves‑
tigate CAVD in vitro, and will make a useful contribution to 
increasing current understanding of the pathophysiological 
process.
Introduction
Calcific aortic valve disease (CAVD) involves gradual thick‑
ening of the aortic valve leaflet (aortic sclerosis) and severe 
calcification, impairing leaflet motion (aortic stenosis) (1). 
CAVD is a prevalent heart valve disease, present in almost 
30% of adults over 65 years, increasing to around 40‑50% 
in those over 75 years (2‑4). Dysfunctional heart valves 
frequently require surgical replacement using mechanical or 
bioprosthetic valves, however these are prone to failure over 
time due to structural or thrombosis‑related problems (5). 
Presently, CAVD is considered an actively regulated and 
progressive disease (6). The development of this disease is 
thought to be initiated by injury, inflammation and lipid depo‑
sition in the valve, followed by a propagation phase in which 
factors promoting calcification and osteogenesis drive disease 
progression (7,8). The increased mechanical stress and injury 
caused by this early calcification event may then elicit further 
calcification, leading to a continuous cycle of valve calcifica‑
tion (9). 
Valve interstitial cells (VICs) are the predominant cell type 
in the aortic valves, and play a major role in CAVD progres‑
sion (7,10). The underlying mechanisms of CAVD share many 
similarities with that of physiological bone formation (11). 
VICs are thought to acquire osteoblastic characteristics during 
the propagation phase of aortic stenosis, following inflamma‑
tion (7,9). A number of studies have established the ability of 
VICs to undergo osteogenic trans‑differentiation and calcifica‑
tion (12‑14). Despite this knowledge, the pathways underlying 
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the initiation and progression of CAVD remain unclear, and 
studies are needed to elucidate the mechanisms underpinning 
early disease pathogenesis.
The in vitro calcification of primary porcine (15‑17), 
human (14,18,19), rat (20‑22) and bovine (23,24) VICs is 
commonly used as models of aortic valve calcification. 
However, to date, the application of a cell line to interrogate 
VIC function has not been reported. Cell lines offer a valuable 
alternative to primary cells isolated directly from animals, 
reducing experimental variation and animal use. To our 
knowledge this is the first study reporting the generation and 
evaluation of the calcification potential of immortalised VIC 
lines derived from sheep (SAVIC) and rat (RAVIC).
Materials and methods
Ethics statement. All animal work was approved by The Roslin 
Institute's and the University of Edinburgh's Protocols and 
Ethics Committees. The animals were maintained in accor‑
dance with UK Home Office guidelines under the regulations 
of the Animal (Scientific Procedures) Act 1986.
Establishment of sheep and rat valve interstitial cell lines. 
Sheep primary aortic VICs were harvested from a 4‑year‑old 
Scottish mule sheep (generated from a Bluefaced Leicester sire 
and Scottish Blackface dam cross; Dryden Farm, Midlothian, 
UK). Rat aortic VICs were isolated from aortic valve leaflets 
dissected from the hearts of eight 5‑week‑old male Sprague 
Dawley rats as previously described (22). Sheep and rat 
valve leaflets were digested in 0.6 mg/ml collagenase Type II 
(Worthington, New Jersey USA) for 30 min and washed in 
Hanks' Balanced Salt Solution (HBSS; Life Technologies, 
Paisley, UK) to remove valve endothelial cells. The leaflets were 
subsequently digested with 0.6 mg/ml collagenase Type II for 
a further 1 h to release the VICs. Cells were pelleted at 300 x g 
for 5 min, before resuspension in growth medium consisting 
of Dulbecco's Modified Eagle Medium: Nutrient Mixture F‑12 
(DMEM/F12; Life Technologies) supplemented with 10% 
heat‑inactivated foetal bovine serum (FBS; Life Technologies) 
and 1% gentamicin (Life Technologies), and cultured at 37˚C 
in a humidified atmosphere of 95% air/5% CO2 and grown for 
four passages.
Immortalised cell lines were established by Capital 
Biosciences (Gaithersburg, Maryland, USA) from the primary 
sheep and rat VICs through transduction with recombinant 
lentivirus encoding Simian virus (SV40) large and small 
T antigens (sheep), or large T antigen only (rat). The non‑clonal 
cell lines were derived from multiple founder cells. Following 
continuous culture to 10 passages, transgene expression was 
confirmed by real‑time quantitative PCR (RT‑qPCR) for the 
expression of SV40 large T antigen (Capital Biosciences). 
The resulting cell lines were designated SAVIC (sheep; 
SVIC‑SVTta) and RAVIC (rat; RVIC‑SV40T).
SAVIC and RAVIC cell culture. SAVIC and RAVIC cells were 
seeded in growth media in multi‑well plates at a density of 
1.11x104 cells/cm2. Calcification was induced as described 
previously (22,25). Cells were grown to 80% confluence (Day 0), 
before treating with control (1.05 mM Ca/0.95 mM Pi) or 
test media: 1.5 to 3.6 mM calcium (Ca) and/or 1.5 to 2.5 mM 
phosphate (Pi). CaCl2 and Na2HPO4/NaH2PO4 (Sigma‑Aldrich, 
Dorset, UK) were used to supplement ionic calcium and 
phosphate in the media. To study the effect of calcification 
inhibitors and bisphosphonates on VIC calcification, SAVICs 
were exposed to inorganic pyrophosphate (PPi) and etidronate 
(both 0.1 mM; Sigma‑Aldrich). Cells were incubated for up to 
7 days in a humidified atmosphere of 95% air/5% CO2, and the 
medium was changed every second/third day.
Detection of calcification. Calcium deposition was quanti‑
fied based on a previously described method (26,27). Cells 
were washed twice with phosphate buffered saline (PBS) 
and decalcified with 0.6 M HCl at room temperature for 2 h. 
Free calcium was determined colorimetrically by a stable 
interaction with phenolsulphonethalein, using a commercially 
available kit (Randox Laboratories Ltd., County Antrim, 
UK), and corrected for total protein concentration (Bio‑Rad 
Laboratories Ltd., Hemel Hempstead, UK) following solu‑
bilisation with 0.1 M NaOH/0.1% SDS. Absorbances were 
measured using a Synergy HT microplate reader (BioTek, 
Swindon UK) at 570 nm (calcium) and at 690 nm (protein).
Fluorescent immunocytochemical staining. To confirm reten‑
tion of mesenchymal phenotype, cell monolayers cultured on 
glass coverslips were fixed with 4% paraformaldehyde (PFA) 
and washed with phosphate‑buffered saline (PBS). Fixed cells 
were permeabilised with 0.3% Triton X‑100 (Sigma‑Aldrich) 
and incubated with rabbit polyclonal anti‑α‑smooth muscle 
actin (α‑SMA; catalogue #ab5694; 1:100; Abcam, Cambridge, 
UK), mouse monoclonal anti‑vimentin (catalogue #V6384; 
Figure 1. Expression of valve interstitial cell markers in SAVICs. Positive 
fluorescent staining for (A) vimentin and (B) alpha‑smooth muscle actin 
(α‑SMA) in the sheep aortic valve interstitial cell line (SAVIC). (C) No 
expression of valve endothelial cell (VEC) marker, CD31, was observed. 
Representative images of (D) mouse IgG and (E and F) rabbit IgG negative 
controls. DAPI was used as a counterstain. Scale bar=100 µm.
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1:900; Sigma‑Aldrich) or rabbit polyclonal anti‑cluster of differ‑
entiation 31 (CD31; 1:900; Abcam, Cambridge, UK) overnight 
at 4˚C. After washing, cells were incubated with Alexa Fluor® 
488 donkey‑anti‑rabbit antibody (catalogue #A‑21,206; 1:250; 
ThermoFisher Scientific) or Alexa Fluor® 594 goat‑anti‑mouse 
antibody (catalogue #A‑110,055; 1:250; ThermoFisher 
Scientific) for 1 h in the dark. Glass coverslips were mounted 
onto slides with Prolong Gold Anti‑Fade Reagent containing 
DAPI (Life Technologies). Slides were examined using a Leica 
DMLB fluorescence microscope (Leica Geosystems, Milton 
Keynes, UK). In place of the primary antibody, control cells 
were incubated with non‑immune mouse or rabbit IgG (2 µg 
IgG/ml, Sigma‑Aldrich).
Real‑time quantitative PCR. RNA extraction was performed 
using the RNeasy Mini kit (Qiagen, West Sussex, UK), 
according to the manufacturer's instructions. RNA abundance 
was quantified, RNA was reverse transcribed, and the expres‑
sion of selected genes were quantified via RT‑qPCR employing 
the SYBR green detection method (PrecisionPLUS mastermix, 
Primerdesign Ltd, Southampton, UK), measured on a 
Stratagene Mx3000P (Agilent Technologies, Stockport, UK), 
as previously reported (28,29). Sheep primers for Runt‑related 
transcription factor 2 (RUNX2; Forward 5'‑CTC CTC CAT CCA 
TCC ACT CC‑3'; Reverse 5'‑CAG AGG CAG AAG TCA GAG 
GT‑3') and Matrix Gla protein (MGP; Forward 5'‑ACA ACA 
GAG ATG GAG AGC GA‑3'; Reverse 5'‑CGG AAA TAA CGG 
TCG TAG GC‑3') were designed via Primer3 (http://primer3.
ut.ee/) to span exon‑exon junctions, and obtained from 
Invitrogen (Paisley, UK). Primers for sheep glyceralde‑
hyde 3‑phosphate dehydrogenase (GAPDH; sequences not 
disclosed), tyrosine 3‑monooxygenase (YWHAZ; sequences 
not disclosed), and sodium‑dependent phosphate transporter 
1 (PiT1; also known as SLC20A1; Forward 5'‑ACA TCT TGA 
ACG CCG CTA‑3'; Reverse 5'‑AGT AGC AGC AAT AGC AGT 
GGT A‑3') were obtained from Primerdesign Ltd. Sheep 
expression data were normalised against the geometric mean 
of GAPDH and YWHAZ. Rat primers for Gapdh, Mgp, and 
Runx2 were obtained from Qiagen (sequences not disclosed; 
QuantiTect primers, Qiagen). Rat Pit1 primers were acquired 
from Primerdesign Ltd. (sequences not disclosed). Rat expres‑
sion data were normalised against Gapdh. The ΔΔCq method 
was used to analyse relative gene expression (30).
Statistical analysis. All statistical analyses were performed 
using Minitab 17 (Minitab Inc., Coventry, UK). General Linear 
Model (GLM) analysis incorporating pairwise comparisons 
and the Student's t‑test were used to assess the data. Data 
are presented as mean ± standard error of the mean (SEM). 
P<0.05 was considered to be statistically significant, and 
P‑values are represented as: *P<0.05; **P<0.01; ***P<0.001.
Results
SAVICs express VIC markers. Cells showed positive immu‑
nohistochemical staining for vimentin (Fig. 1A) and α‑SMA 
(Fig. 1B), in agreement with previous reports of primary VIC 
cultures (31,32). Cells were negative for the endothelial marker 
CD31 (Fig. 1C).
Calcification of SAVICs. Initial studies were undertaken 
to determine whether the calcification of SAVICs could be 
induced when cultured in the presence of calcifying medium 
containing Ca and/or Pi (Fig. 2A). Ca potently induced the 
calcification of SAVICs from 2.7 mM (1.9 fold; P<0.001; n=6; 
Fig. 2A) whereas Pi treatment alone had no effect (Fig. 2A). 
The treatment of VICs with Ca and Pi together had a syner‑
gistic effect on VIC calcification from 2.7 mM Ca/2.0 mM Pi 
(22.2 fold; P<0.001; n=6; Fig. 2B).
Gene expression in early calcification in vitro. Next, gene 
expression studies were undertaken in calcifying SAVICs to 
investigate the expression profile of key genes associated with 
vascular calcification. Expression of the gene encoding the 
Figure 2. SAVICs undergo calcification in vitro. Calcium deposition determined by HCl leaching (µg/mg protein) in VICs treated with (A) calcium (Ca) 
alone (1.5‑5.4 mM) and phosphate (Pi) alone (1.5‑5.0 mM), and (B) calcium and phosphate in combination (1.5 to 3.6 mM Ca/0.95 to 2.5 mM Pi). Results are 
presented as mean ± SEM. **P<0.01; ***P<0.001 compared with control; n=6.
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master osteoblastic transcription factor, RUNX2, was signifi‑
cantly increased from 4.5 mM Ca (1.3 fold; P<0.05; n=6; 
Fig. 3A) compared to control culture conditions. Expression 
of sodium‑dependent phosphate transporter 1 gene (PiT1) 
was significantly increased at 5.4 mM Ca (1.2 fold; P<0.05; 
n=6; Fig. 3B). In contrast, a decrease in the expression of the 
calcification inhibitor Matrix Gla Protein gene (MGP) was 
noted from 3.6 mM Ca (1.3 fold; P<0.01; n=6; Fig. 3C).
Inhibition of SAVICs calcification by pyrophosphate and 
etidronate. Further experiments investigated whether the 
calcification of SAVICs could be reduced using recognised 
inhibitors of calcification.
As CAVD is a consequence of hydroxyapatite formation 
and deposition in the aortic valve, we examined the effects of 
PPi (0.01‑1 mM; Fig. 4A) and the bisphosphonate etidronate 
(0.01‑1 mM; Fig. 4B), both established inhibitors of hydroxy‑
apatite formation (33‑35) on SAVIC calcification. A significant 
decrease in calcium deposition was observed at 1 mM PPi 
(1.8 fold; P<0.01; n=6; Fig. 4A). Additionally, following expo‑
sure to 1 mM etidronate, a significant reduction in calcium 
deposition (3.2 fold; n=6; P<0.01) was observed, confirming 
the inhibitory effect of this bisphosphonate on valve calcifica‑
tion in vitro (Fig. 4B).
Additional RAVIC studies. We further corroborated the 
application of immortalised VICs as an in vitro model of 
aortic valve calcification through the generation of a rat 
immortalised VIC cell line, RAVIC. A presented in Fig. 5, 
RAVICs also showed positive immunohistochemical staining 
for vimentin (Fig. 5A) and α‑SMA (Fig. 5B), and were nega‑
tive for the endothelial marker CD31 (data not shown).
Analogous to our findings with the SAVICs, Ca markedly 
induced the calcification of RAVICs from 2.7 mM (4.6 fold; 
P<0.01; n=6; Fig. 5E) and Pi treatment alone had no effect 
(Fig. 5E). Furthermore, the treatment of RAVICs with Ca 
and Pi together had a synergistic effect on cell calcification 
(2.7 mM Ca/2.0 mM Pi; 82.2 fold; P<0.001; n=6; Fig. 5F). 
5.4 mM Ca treatment induced a significant increase in the 
mRNA expression of Runx2 and Pit1 (1.5 fold; P<0.01, 
and 4.7 fold; P<0.001, respectively; Fig. 5G and H), with a 
concomitant reduction in Mgp expression (3.2 fold; P<0.001; 
Fig. 5I).
Discussion
The calcification of primary porcine (15‑17), human (14,18,19), 
rat (20‑22) and bovine (23,24) VICs in 10% serum, inducing 
an activated phenotype, is frequently employed to produce 
in vitro models of aortic valve calcification. Compared to 
cell lines, primary cultures exhibit slow growth and cannot 
be used beyond a limited number of passages due to senes‑
cence and phenotypic changes that occur during culture. 
Furthermore, the use of primary cells requires animal sacrifice 
Figure 3. Upregulation of osteogenic gene marker expression in calcifying SAVICs. Fold change in the mRNA expression of (A) RUNX2, (B) PIT1, and 
(C) MGP in sheep aortic valve interstitial cell line (SAVIC) treated with Ca (2.7‑5.4 mM) for 48 h. Results are presented as mean ± SEM. *P<0.05, **P<0.01; 
***P<0.001 compared to control; n=6.
Figure 4. Modulation of SAVIC calcification with established calcification 
inhibitors. Effect of (A) pyrophosphate (PPi) and (B) etidronate exposure on 
SAVIC calcification in vitro, following culture for 7 days under calcifying 
conditions (2.7 mM Ca/2.0 mM Pi). Results are presented as mean ± SEM; 
**P<0.01; n=6.
MOLECULAR MEDICINE REPORTS 5
and is labour intensive, costly, and time consuming (36). A 
number of studies have employed the mouse vascular smooth 
muscle cell line, MOVAS‑1, to investigate arterial calcification 
in vitro (28,37,38). As yet, however, no published studies have 
employed immortalized VIC cell lines to investigate aortic 
valve calcification. In the present study, we have character‑
ized the in vitro calcification potential of immortalised sheep 
(SAVIC) and rat (RAVIC) VIC cell lines.
Our data have established that calcification of SAVICs and 
RAVICs can be induced in the presence of calcifying medium 
containing high concentrations of calcium and phosphate. This 
was demonstrated through standard assays of in vitro vascular 
calcification (28,39,40), verifying these cell lines as a feasible 
and relevant in vitro model of aortic valve calcification.
Calcified SAVICs and RAVICs showed increased gene 
expression of RUNX2 and PiT1, recognized markers of vascular 
calcification, with a concomitant reduction in the expression 
of MGP, an established calcification inhibitor. RUNX2 is an 
early marker of vascular calcification, initiating osteoblastic 
differentiation via the upregulation of mineralization proteins, 
including osteopontin and osteocalcin (10,41). Increased 
PiT1 expression leads to elevated intracellular phosphate 
and induces the osteogenic conversion of vascular smooth 
muscle cells (VSMCs) (42). Conversely, down‑regulation of 
PiT1 gene expression by siRNA silencing has been shown 
to reduce phosphate uptake and inhibit phosphate‑induced 
VSMC phenotypic transition and calcification (42). MGP is a 
γ‑carboxyglutamic acid‑rich and vitamin K‑dependent protein, 
and is proposed to block calcification by antagonising bone 
morphogenetic protein signaling (10,43). Mouse models that 
lack MGP develop arterial calcification that results in blood 
vessel rupture, as well as ectopic cartilage calcification (44). 
Additionally, circulating MGP levels have been shown to be 
reduced in aortic valve disease patients (45). Taken together, 
our data suggests that the culture of SAVICs and RAVICs in 
calcifying medium is an appropriate in vitro model with which 
to study the processes leading to aortic valve calcification.
Using known molecular inhibitors, we have also shown that 
functional studies can be performed in SAVICs. Pyrophosphate 
is a potent inhibitor of the calcification of primary VSMCs (46) 
Figure 5. Characterisation of RAVICs confirms the use of immortalised VICs as an in vitro CAVD model. Positive staining for (A) vimentin and (B) α‑SMA 
in the rat aortic valve interstitial cell line (RAVIC). Representative images of (C) mouse and (D) rabbit IgG negative control. DAPI was used as a counterstain. 
Scale bar=100 µm. Calcium deposition determined by HCl leaching (µg/mg protein) in VICs treated with (E) calcium (Ca) alone (1.5‑5.4 mM) and phosphate 
(Pi) alone (1.5‑5.0 mM) and (F) calcium and phosphate in combination (1.5 to 3.6 mM Ca/0.95 to 2.5 mM Pi). Fold change in the mRNA expression of 
(G) Runx2 (H) PiT1 and (I) Mgp in VICs treated with Ca (2.7‑5.4 mM) for 48 h. Results are presented as mean ± SEM. *P<0.05, **P<0.01; ***P<0.001 compared 
to control; n=6.
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and VICs (23). The bisphosphonate etidronate, an inhibitor of 
hydroxyapatite formation and a non‑hydrolysable analogue 
of PPi, has also been reported to inhibit the calcification of 
MOVAS‑1 cells and NIH3T3 cells (28,47). The reduction in 
calcification observed in SAVICs following treatment with 
PPi and etidronate therefore establishes this cell line as highly 
appropriate for modeling aortic valve calcification.
The severe clinical implications of CAVD are widely 
recognized. Nonetheless, the underlying mechanisms have not 
been fully determined and effective therapeutic strategies that 
may prevent or possibly reverse aortic valve calcification have 
yet to be developed. The SAVIC and RAVIC lines are conve‑
nient and inexpensive models in which to investigate aortic 
valve calcification in vitro, and will make a valuable contribu‑
tion to expanding our knowledge of this pathological process.
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